Eli Lilly and Company
IL-17 antibody formulations and methods of treatment using same
Last updated:
Abstract:
The present invention provides pharmaceutical formulations for anti-IL-17 antibodies. These anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.
Status:
Grant
Type:
Utility
Filling date:
10 Nov 2017
Issue date:
12 Nov 2019